HUE032660T2 - Sztirilpiridin-származékok és azok alkalmazása amiloid plakkok megkötésére és leképezésére - Google Patents

Sztirilpiridin-származékok és azok alkalmazása amiloid plakkok megkötésére és leképezésére Download PDF

Info

Publication number
HUE032660T2
HUE032660T2 HUE11152124A HUE11152124A HUE032660T2 HU E032660 T2 HUE032660 T2 HU E032660T2 HU E11152124 A HUE11152124 A HU E11152124A HU E11152124 A HUE11152124 A HU E11152124A HU E032660 T2 HUE032660 T2 HU E032660T2
Authority
HU
Hungary
Prior art keywords
compound
alkyl
mmol
compounds
hydroxy
Prior art date
Application number
HUE11152124A
Other languages
English (en)
Inventor
Hank F Kung
Mei-Ping Kung
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of HUE032660T2 publication Critical patent/HUE032660T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (5)

  1. Szí i rí Ip i ri di π -s zárm azékok és azok alkalmazása amüoid piakkok megkötésére és leképezésére Szabadalmi igénypontok 1. Λ
    képletü vegyület.
  2. 2. Az 1. igénypont szerinti vegyület et tartalmazó gyógyászati készítmény.
  3. 3. Diagnosztikai készítmény amikkel lerakódások leképezésére, mely egy k igénypont szerinti radioaktívon jelölt vegyüíetet tartalmaz.
  4. 4. A 3. igénypont szerinti diagnosztikai készítmény amüoid lerakódások leképezésében törté-no alkalmazásra* melynek sorén: a, egy emlősbe a diagnosztikai készítmény detektálható mennyiségét visszük be; b, megfelelő időt biztosítunk a jelölt vegyűletnek az amiloíd lerakódásokkal történő kapcsolódására: és e. meghatározzuk az egy vagy több amüoid lerakodással kapcsolódott jelölt vegyüíetet.
  5. 5. Λ '2. igénypont szerinti készítmény emlősben amiloid plakk aggregáció gátlásában történő alkalmazásra.
HUE11152124A 2006-03-30 2007-03-26 Sztirilpiridin-származékok és azok alkalmazása amiloid plakkok megkötésére és leképezésére HUE032660T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78715606P 2006-03-30 2006-03-30

Publications (1)

Publication Number Publication Date
HUE032660T2 true HUE032660T2 (hu) 2017-10-30

Family

ID=38326579

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE11152124A HUE032660T2 (hu) 2006-03-30 2007-03-26 Sztirilpiridin-származékok és azok alkalmazása amiloid plakkok megkötésére és leképezésére
HUS1300028C HUS1300028I1 (hu) 2006-03-30 2013-06-27 Sztiril-piridin-származékok és alkalmazásuk amyloid-plakkok megkötésére és leképezésére

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS1300028C HUS1300028I1 (hu) 2006-03-30 2013-06-27 Sztiril-piridin-származékok és alkalmazásuk amyloid-plakkok megkötésére és leképezésére

Country Status (34)

Country Link
US (3) US7687052B2 (hu)
EP (3) EP2363392B1 (hu)
JP (1) JP5290954B2 (hu)
KR (1) KR101376807B1 (hu)
CN (1) CN101522624B (hu)
AT (1) ATE539060T1 (hu)
AU (1) AU2007243712B2 (hu)
BR (1) BRPI0710225B1 (hu)
CA (1) CA2644530C (hu)
CR (1) CR10329A (hu)
CY (3) CY1113048T1 (hu)
DK (2) DK2363392T3 (hu)
EA (1) EA017898B1 (hu)
EC (1) ECSP088783A (hu)
ES (2) ES2378785T3 (hu)
FR (1) FR13C0034I2 (hu)
GT (1) GT200800201A (hu)
HR (2) HRP20120135T1 (hu)
HU (2) HUE032660T2 (hu)
IL (1) IL193567A (hu)
LT (1) LT2363392T (hu)
LU (1) LU92232I2 (hu)
MX (1) MX2008012527A (hu)
NO (2) NO342090B1 (hu)
NZ (1) NZ570887A (hu)
PL (2) PL1999109T3 (hu)
PT (2) PT2363392T (hu)
RS (2) RS52222B (hu)
SG (1) SG173338A1 (hu)
SI (2) SI2363392T1 (hu)
TW (1) TWI399366B (hu)
UA (1) UA97802C2 (hu)
WO (1) WO2007126733A2 (hu)
ZA (1) ZA200807955B (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE539060T1 (de) * 2006-03-30 2012-01-15 Univ Pennsylvania Styrylpyridinderivate und ihre verwendung zur bindung und abbildung von amyloider plaque
JP5322180B2 (ja) * 2007-07-04 2013-10-23 国立大学法人東北大学 フッ素およびヒドロキシ基で置換されたアルコキシ基を有するｐｅｔプローブ
US8557222B2 (en) 2008-04-04 2013-10-15 Avid Radiopharmaceuticals, Inc. Radiopharmaceutical imaging of neurodegenerative diseases
DK2381967T3 (en) * 2008-12-31 2017-03-27 Avid Radiopharmaceuticals Inc Synthesis of 18F-radiolabelled styryl pyridines from tosylate precursors and stable pharmaceutical compositions thereof
JP2012532164A (ja) * 2009-07-10 2012-12-13 バイエル ファーマ アクチエンゲゼルシャフト 放射性トレーサーの精製のための低‐中圧液体クロマトグラフィーの使用
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
CA2785576C (en) * 2009-12-23 2017-12-05 Piramal Imaging Sa Formulations suitable for pet imaging with hydrophobic pet agents
WO2011141515A1 (en) 2010-05-14 2011-11-17 Bayer Pharma Aktiengesellschaft Diagnostic agents for amyloid beta imaging
JP2013532136A (ja) 2010-06-04 2013-08-15 ピラマル イメージング ソシエテ アノニム Ｆ−１８標識アミロイド・ベータ・リガンドの製造方法
TWI504414B (zh) 2010-06-04 2015-10-21 Bayer Schering Pharma Ag 生產Ｆ－１８標記之Ａβ配位體之方法
EA201201647A1 (ru) * 2010-06-04 2013-05-30 Пирамаль Имэджинг Са Способ получения f-18 меченных лигандов бета-амилоида
CA2801530C (en) 2010-06-04 2017-09-12 Piramal Imaging Sa Method for production of f-18 labeled amyloid beta ligands
CN101891674B (zh) * 2010-06-24 2012-11-14 山东大学 4-苯乙烯基吡啶类化合物及其制备方法与应用
EP3263136A1 (en) * 2010-10-12 2018-01-03 Mayo Foundation for Medical Education and Research Imaging of meningiomas using stilbene, or biphenylalkyne derivatives
US20140079635A1 (en) * 2011-03-30 2014-03-20 Case Western Reserve University Molecular probes for detecting lipid composition
CA2831331C (en) * 2011-04-21 2019-10-15 The Regents Of The University Of California Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles
BR112014009013A2 (pt) 2011-10-19 2017-05-02 Piramal Imaging Sa método melhorado para a produção de ligandos aß rotulados por f-18
EP2836241B1 (en) 2012-04-10 2019-02-20 Lantheus Medical Imaging, Inc. Radiopharmaceutical synthesis methods
JP6099045B2 (ja) * 2013-04-30 2017-03-22 国立大学法人京都大学 トリアゾロピリミジン誘導体化合物
JP6041751B2 (ja) * 2013-05-07 2016-12-14 日本メジフィジックス株式会社 スチリルピリジン誘導体化合物
JP2014218454A (ja) * 2013-05-07 2014-11-20 日本メジフィジックス株式会社 スチリルピリジン誘導体化合物
CN103645254B (zh) * 2013-11-28 2015-01-07 江苏省原子医学研究所 一种Aβ斑块显像剂前体AV45的含量分析方法
PT3143011T (pt) * 2014-05-13 2021-04-26 Hoffmann La Roche Compostos heterocíclicos deuterados e a sua utilização como agentes de imagiologia
EP3337475A4 (en) * 2015-08-18 2019-04-10 The Regents of The University of California NITROXIDE WITH AMYLOID BINDING AGENT FOR IMAGING AND THERAPEUTIC USES
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
CN109400615B (zh) * 2017-08-18 2021-07-16 上海交通大学医学院附属新华医院 一种靶向β-淀粉样蛋白的香豆素类化合物及其制备与应用
CN108299287A (zh) * 2018-01-02 2018-07-20 北京师范大学 与Aβ斑块具有高亲和力的N2S2类吡啶基苯乙烯化合物
CN114805190A (zh) * 2022-06-08 2022-07-29 吉林大学第一医院 一种甲基苯胺类Aβ蛋白显像剂的双柱合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000963A1 (en) * 1990-07-12 1992-01-23 Yoshitomi Pharmaceutical Industries, Ltd. Styryl compounds and use thereof as medicine
JPH0545875A (ja) * 1991-08-08 1993-02-26 Konica Corp 感光性組成物
US6020436A (en) * 1993-03-09 2000-02-01 The Chromaline Corporation Photosensitive resin composition
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
AU2001239544A1 (en) * 2000-03-22 2001-10-03 Bf Research Institute, Inc. Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same
US8007954B2 (en) 2000-11-09 2011-08-30 The Trustees Of The University Of Pennsylvania Use of sulfur-containing fuels for direct oxidation fuel cells
JP2002182254A (ja) 2000-12-18 2002-06-26 Fuji Photo Film Co Ltd 非線形光学材料とその製造方法
WO2003018070A1 (en) * 2001-08-27 2003-03-06 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use for binding and imaging amyloid plaques
CN1672283A (zh) 2002-06-06 2005-09-21 宾夕法尼亚州大学理事会 陶瓷阳极及其制造方法
AU2003258612A1 (en) * 2002-08-14 2004-03-03 4Sc Ag Pyrimidones as antiviral agents
JP4482352B2 (ja) 2004-03-11 2010-06-16 本田技研工業株式会社 固体高分子型燃料電池
AU2005316421B2 (en) * 2004-12-17 2012-04-05 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use for binding and imaging amyloid plaques
WO2006078384A2 (en) * 2004-12-17 2006-07-27 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use
WO2007002540A2 (en) * 2005-06-24 2007-01-04 Kung Hank F Radiolabeled-pegylation of ligands for use as imaging agents
ATE539060T1 (de) * 2006-03-30 2012-01-15 Univ Pennsylvania Styrylpyridinderivate und ihre verwendung zur bindung und abbildung von amyloider plaque
US20080253967A1 (en) * 2007-04-13 2008-10-16 Kung Hank F Halo-Stilbene Derivatives And Their Use For Binding And Imaging Of Amyloid Plaques

Also Published As

Publication number Publication date
HUS1300028I1 (hu) 2017-08-28
EA200870389A1 (ru) 2009-04-28
PL2363392T3 (pl) 2017-10-31
ES2628882T3 (es) 2017-08-04
EP1999109B1 (en) 2011-12-28
US20130129624A1 (en) 2013-05-23
TWI399366B (zh) 2013-06-21
PT1999109E (pt) 2012-03-16
US7687052B2 (en) 2010-03-30
EP1999109A2 (en) 2008-12-10
KR20080106564A (ko) 2008-12-08
HRP20120135T1 (hr) 2012-03-31
NO2018030I1 (no) 2018-09-11
CY1119048T1 (el) 2018-01-10
NZ570887A (en) 2011-05-27
FR13C0034I2 (fr) 2014-03-07
US8506929B2 (en) 2013-08-13
US20080038195A1 (en) 2008-02-14
UA97802C2 (uk) 2012-03-26
TW200838852A (en) 2008-10-01
SI1999109T1 (sl) 2012-04-30
FR13C0034I1 (hu) 2013-08-09
MX2008012527A (es) 2008-10-14
SI2363392T1 (sl) 2017-09-29
ZA200807955B (en) 2012-11-28
ATE539060T1 (de) 2012-01-15
BRPI0710225B1 (pt) 2021-07-13
CN101522624B (zh) 2013-11-06
CA2644530C (en) 2015-05-19
ES2378785T3 (es) 2012-04-17
AU2007243712A1 (en) 2007-11-08
NO342090B1 (no) 2018-03-19
KR101376807B1 (ko) 2014-03-20
PL1999109T3 (pl) 2012-05-31
PT2363392T (pt) 2017-06-15
EP2363391A1 (en) 2011-09-07
SG173338A1 (en) 2011-08-29
EA017898B1 (ru) 2013-04-30
DK2363392T3 (en) 2017-07-03
JP5290954B2 (ja) 2013-09-18
CY1113048T1 (el) 2015-11-04
LT2363392T (lt) 2017-07-25
AU2007243712B2 (en) 2013-01-10
BRPI0710225A2 (pt) 2011-08-02
RS56171B1 (sr) 2017-11-30
HRP20170857T1 (hr) 2017-12-01
EP2363392A1 (en) 2011-09-07
IL193567A0 (en) 2009-05-04
WO2007126733A2 (en) 2007-11-08
CA2644530A1 (en) 2007-11-08
RS52222B (en) 2012-10-31
IL193567A (en) 2014-03-31
LU92232I9 (hu) 2019-01-15
DK1999109T3 (da) 2012-04-02
ECSP088783A (es) 2008-10-31
NO20084590L (no) 2008-12-29
CN101522624A (zh) 2009-09-02
CY2013024I1 (el) 2015-11-04
WO2007126733A3 (en) 2008-03-06
GT200800201A (es) 2009-08-20
LU92232I2 (fr) 2013-08-26
US8840866B2 (en) 2014-09-23
US20090123369A1 (en) 2009-05-14
EP2363392B1 (en) 2017-05-03
CR10329A (es) 2008-10-29
JP2009532349A (ja) 2009-09-10
CY2013024I2 (el) 2015-11-04

Similar Documents

Publication Publication Date Title
DK2363392T3 (en) Styryl pyridine derivatives and their use in bonding and imaging of amyloid plaques
US7297820B2 (en) Stilbene derivatives and their use for binding and imaging amyloid plaques
AU2002323417A1 (en) Stilbene derivatives and their use for binding and imaging amyloid plaques
US20110158907A1 (en) Diphenyl-heteroaryl derivatives and their use for binding and imaging amyloid plaques